A Spanish coronavirus research project, which uses a variant of the virus used to create the vaccine against smallpox, has shown 100 per cent efficacy in mice, according to a report in the prestigious Journal of Virology.
This compares to the 95 per cent offered by the Pfizer-BioNTech and Moderna vaccines that are already being distributed in Europe and much higher than the 70 per cent immunity of the AstraZeneca / University of Oxford vaccine.
As reported this Thursday by Spain’s Higher Council for Scientific Research (CSIC) the project of scientists Mariano Esteban and Juan García Arriaza is ready to advance towards clinical tests in humans once approval is received from the Spanish Medicines Agency.
The inoculation of the first 100 volunteers could start in a few weeks if permission is granted.
However, experts have said that if all human clinical trials went to plan – and there were no setbacks – it is unlikely it would be available before 2022.